SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Albert Einstein

PatientAlbert Einstein
Date of birth1956-03-14
IdentifiersMRN HR-ET012-SYN; SSN (made up) 000-12-6650
Document date2026-07-14
AuthorClementine Ward, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review of blood pressure, cholesterol, and smoking cessation. [S]

History of Present Illness

Mr. Einstein returns about four months after his first visit. He has had no tobacco since his quit date and has had no cravings strong enough to need more than one or two lozenges a day for the past month; he still holds an empty pipe at his desk. His home blood pressure readings average 124/74 on amlodipine 5 mg and losartan 100 mg. He takes atorvastatin 40 mg and aspirin 81 mg without muscle aches, bruising, or bleeding. The back strain six weeks ago settled within ten days, and he has had no abdominal, back, or flank pain since. The lipid panel was not drawn in the first twelve weeks on atorvastatin, because no standing order was placed after the four-week visit; it was drawn today. [S]

ElementDetail
TobaccoTobacco-free since the quit date; one or two lozenges a day
Blood pressureHome average 124/74
MedicinesAmlodipine 5 mg, losartan 100 mg, atorvastatin 40 mg, aspirin 81 mg; no side effects
Interval illnessLow back strain six weeks ago, resolved

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, fainting, or leg pain on walking
GastrointestinalNegativeNo abdominal pain or black stools
MusculoskeletalNegativeBack pain resolved; no muscle aches
HematologicNegativeNo easy bruising or bleeding

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet by mouth each morningOral route2025-05-20activeS
Losartan 50 mg oral tablet, one tablet dailyOne tablet by mouth each morningOral route2026-03-24 to 2026-04-21completedS
Losartan 100 mg oral tablet, one tablet dailyOne tablet by mouth each morningOral route2026-04-21activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet by mouth each eveningOral route2026-03-24activeS
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet by mouth daily with foodOral route2026-04-21activeS
Nicotine 14 mg/24 hour transdermal patch, one patch dailyApply one new patch each morningTopical route2026-03-24 to 2026-07-14completedS
Nicotine 7 mg/24 hour transdermal patch, one patch dailyApply one new patch each morningTopical route2026-07-14 to 2026-09-22completedS
Nicotine 2 mg lozenge as needed for cravingsDissolve one lozenge in the mouth for a craving, no more often than every 2 hours and no more than 20 a dayOral route2026-03-24 to 2026-09-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-14Body height172cmS
2026-07-14Body weight79.4kgS
2026-07-14Body mass index (BMI) [Ratio]26.8kg/m2S
2026-07-14Systolic blood pressure126mm[Hg]S
2026-07-14Diastolic blood pressure76mm[Hg]S
2026-07-14Heart rate68/minS
2026-07-14Respiratory rate14/minS
2026-07-14Body temperature36.6CelS
2026-07-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-14Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-07-14Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-07-14Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.74-1.35 mg/dLNormalS
2026-07-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M70mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-14Cholesterol [Mass/volume] in Serum or Plasma132mg/dL<=200 mg/dLNormalS
2026-07-14Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
2026-07-14Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation62mg/dL<=129 mg/dLNormalS
2026-07-14Triglyceride [Mass/volume] in Serum or Plasma120mg/dL<=149 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-07-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 79.4 kg
CardiovascularRegular rhythm at 68 per minute; blood pressure 126/76 mmHg
AbdomenPulsatile, non-tender mass above the umbilicus

Problems

ProblemClinical statusVerificationCodeProvenance
Infrarenal abdominal aortic aneurysm, 5.0 cm by duplex ultrasound, found and wrapped at a prior exploratory laparotomy; under surveillance below the repair thresholdactiveconfirmed I71.43S — Synthetic modern coding anchored to the documented aneurysm found and wrapped at his exploratory laparotomy; the diameter and all surveillance are synthetic.
Essential hypertensionactiveconfirmed I10S — Synthetic risk factor in the modern frame; no historical blood pressure is documented in the cited sources.
Nicotine dependence, pipe tobaccoactiveconfirmed F17.290S — Synthetic modern coding anchored to his documented pipe smoking.
Atherosclerosis of the abdominal aorta, with calcified atheroma on CT angiographyactiveconfirmed I70.0S — Synthetic finding on the baseline CT angiography.
Acute low back strain after lifting, with aneurysm symptoms excluded; resolvedresolvedconfirmed S39.012AS — Synthetic intercurrent illness at an unscheduled visit, chosen to teach how new back pain is assessed in a patient with a known aneurysm. It does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingAneurysm diameter by duplex ultrasound (CT if views are poor)Every 6 months at 5.0 to 5.4 cm in men; yearly at 4.0 to 4.9 cmUp to date5.0 cm by duplex ultrasound at the sick visit six weeks ago, unchanged; next scan at six months
ImagingCT angiography for baseline anatomy and repair planningOnce at baseline; again when repair is consideredUp to dateBaseline done; repeat only if repair is considered
ExaminationFemoral and popliteal arteries for a coexisting aneurysmOnce at diagnosisUp to dateNormal on examination; popliteal duplex planned with the six-month scan
ExaminationAneurysm symptoms and tenderness, with the emergency plan reviewedEvery visitCompleted todayNo pain or tenderness since the back strain resolved; emergency plan reviewed
ReferralVascular surgery review and shared decision on elective repairAt baseline, then at a threshold change or yearlyUp to dateShared decision recorded at the four-week visit; review at the six-month scan
ExaminationBlood pressure, target below 130/80Every visitCompleted today126/76 mmHg; at target
Self-managementHome blood pressure readingsBefore each visit while treatment is being adjustedCompleted todayHome average 124/74
LaboratoryMetabolic panel (sodium, potassium, creatinine, eGFR)2 to 4 weeks after starting or changing losartan; then every 6 monthsCompleted todayAfter the losartan increase: sodium 139, potassium 4.7, creatinine 1.10 mg/dL, eGFR 70; next in six months
LaboratoryLipid panel4 to 12 weeks after starting a statin; then yearlyDeferredNot drawn within the 4 to 12 week window after atorvastatin was started, a deviation from the protocol: no standing order was placed at the four-week visit and no visit fell before twelve weeks. Judging by today's result, no harm resulted. Corrective action: standing laboratory orders are placed at each visit for tests due before the next one
LaboratoryLipid panel4 to 12 weeks after starting a statin; then yearlyCompleted todayDrawn today at sixteen weeks: total cholesterol 132, HDL 46, LDL 62, triglycerides 120 mg/dL; LDL down 56 percent and below 70
LaboratoryALTOnce before a statin; then only with symptomsNot indicatedNo muscle or liver symptoms; routine repeat not recommended
LaboratoryHbA1cYearlyUp to date5.6 percent in March; repeat yearly
LaboratoryUrine albumin-to-creatinine ratioYearlyUp to date14 mg/g in March; repeat yearly
Medication safetyStatin adherence and muscle symptomsEvery visitCompleted todayAdherent; no muscle aches
Medication safetyLow-dose aspirin: indication and bleedingEvery visit while taking itCompleted todayNo bruising, black stools, or bleeding
Medication safetyMedication review: avoid fluoroquinolones and anti-inflammatory pain medicinesEvery visitCompleted todayAcetaminophen only for the back strain; no anti-inflammatory or fluoroquinolone use
Self-managementTobacco use and cessation support (5 A's, nicotine replacement)Every visitCompleted todayTobacco-free about fifteen weeks; patch stepped down to 7 mg
Examination12-lead ECGBaseline with hypertension; repeat as indicatedUp to dateNormal at the four-week visit
ExaminationAnkle-brachial indexEvery 2 to 3 years at 65 or older or with a smoking historyDueWith the six-month duplex scan
ExaminationEye examination for hypertensive retinopathyYearlyDueTo be arranged at the wellness visit
ExaminationWeight and BMIEvery visitCompleted today79.4 kg; BMI 26.8

Goal progress:

Guideline basis: The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm (2018); 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease (2022); CMID: Clinical Monitoring Intelligence Database, Hypertension and Hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)

Follow-up: Annual wellness visit in about six weeks. Six-month surveillance visit with duplex ultrasound, popliteal duplex, and ankle-brachial index. Next scheduled visit 2026-08-25: subsequent annual wellness visit. [S]